GeoVax to Report Q3 2025 Financial Results and Provide Business Update on November 13

GeoVax Labs, Inc. will report its financial results for the quarter ended September 30, 2025, following the close of U.S. markets on November 13, 2025. The clinical-stage biotechnology company, which develops multi-antigen vaccines and immunotherapies for infectious diseases and cancer, will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Investors and stakeholders can access the live conference call by registering in advance through the company's designated portal at https://edge.media-server.com/mmc/p/u86rmdmb/. The live audio webcast will also be available via the Events & Presentations section of the company's Investor Relations website at https://www.geovax.com/investors. Telephone participants should register using the provided link to receive dial-in information, a unique passcode, and access instructions. Although registration is not mandatory, participants are encouraged to join ten minutes before the scheduled start time. An archived version of the webcast will be available on the company's website approximately two hours after the call concludes and will remain accessible for at least 90 days.

The upcoming financial report and corporate update hold significant importance for investors and the broader biotechnology sector, as they will provide critical insights into GeoVax's financial health and progress across its clinical pipeline. The company's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials evaluate its potential as a primary vaccine for immunocompromised patients, including those with hematologic cancers, as a booster vaccine for chronic lymphocytic leukemia patients, and as a more robust, durable COVID-19 booster for healthy individuals previously vaccinated with mRNA vaccines.

In oncology, GeoVax's lead clinical program focuses on Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company is also advancing a vaccine targeting Mpox and smallpox, which, based on recent EMA regulatory guidance, may progress directly to Phase 3 clinical evaluation, bypassing Phase 1 and Phase 2 trials. This accelerated pathway could significantly shorten development timelines and potentially bring the vaccine to market faster.

GeoVax maintains a strong intellectual property portfolio with worldwide rights for its technologies and products, providing competitive advantages in the rapidly evolving vaccine and immunotherapy markets. The company's forward-looking statements emphasize its expectations and projections regarding clinical trial outcomes, product efficacy, regulatory approvals, and manufacturing capabilities. However, these statements are subject to various risk factors, including the ability to obtain acceptable clinical trial results, demonstrate product safety and effectiveness, secure regulatory approvals, raise necessary capital, and compete against potentially more effective or easier-to-use products.

The November 13 update will be particularly important for assessing GeoVax's progress in addressing unmet medical needs, especially for immunocompromised populations who may not respond adequately to current COVID-19 vaccines. Success in these areas could have substantial implications for public health and establish new standards for vaccine development in vulnerable patient populations. Additionally, advancements in the company's oncology programs could contribute to the growing field of cancer immunotherapies, potentially offering new treatment options for patients with solid tumors.